LRMR
Larimar TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The constructive case is still regulatory execution: Q2 2026 topline open-label data, Phase 3 screening planned for Q2 2026, first-patient dosing expected around mid-2026, and a June 2026 BLA target together create a visible catalyst stack into mid-2026 [#8-K-2026-03-19][#10-K-2026-03-19].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +14.9.
What can break
FDA could disagree with the accelerated-approval package, require more data, or determine the safety database is inadequate at BLA review.
Momentum
17
Value
41
Sentiment
92
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.20 · Bull $10.00 · Bear $2.20
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $14.40
Why
Momentum17 · Δ7d +5.4
Value41 · Δ7d +0.0
Sentiment92 · Δ7d +14.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
17
26% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+5.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
92
34% active weight
Current posture
7d trendImproving
Δ7d
+14.9
Δ21d
-1.4
Why this grade
Composite grade C. Momentum 17.2 / Value 41.1 / Sentiment 92.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$397.87M
Beta
1.01
Shares Out
104.38M
P/E (TTM) · Derived
-1.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.36
Rev YoY
-
EPS YoY
-28.3%
Gross Margin
-
Op Margin
-
Net Debt
-$132.79M
Current Ratio
4.29
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology